Literature DB >> 24068069

Posterior reversible encephalopathy syndrome: an acute manifestation of systemic lupus erythematous.

Dexter Yak Seng Chan1, Yin Sheng Ong.   

Abstract

Stroke mimickers are common, and they represent a diagnostic dilemma for clinicians. Many, like posterior reversible encephalopathy syndrome (PRES), are easily reversible. The manifestation of PRES is characterised by headaches, convulsions, altered mental functioning and blindness. In most cases, computed tomography of the brain will show hypodense lesions in the parieto-occpitial lobe, which only further confounds the physician. Although this syndrome is uncommon, prompt and accurate recognition allows early treatment, which has been shown to produce favourable outcomes. Herein, we report the case of a 54-year-old woman, who presented with PRES, as an acute manifestation of systemic lupus erythematous (SLE) and lupus nephritis. The patient was initially thought to be experiencing an ischaemic stroke, but the diagnosis was later changed. On management of her underlying condition, her symptoms resolved. PRES should be recognised as an acute emergency manifestation of SLE. It should not be mistaken for an ischaemic stroke as inappropriate treatment could have adverse outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 24068069     DOI: 10.11622/smedj.2013182

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  2 in total

1.  Posterior reversible encephalopathy syndrome following paroxysmal nocturnal hemoglobinuria: a case report and literature review.

Authors:  Dongxue Ding; Kai Li; Guoliang Li; Xiaoyan Long
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Posterior Reversible Encephalopathy Syndrome in Two Omani Children with Underlying Renal Diseases.

Authors:  Mohamed A El-Naggari; Dana Al-Nabhani; Ibtisam El-Nour; Alaa El-Manzalawy; Anas-Alwogud A Abdelmogheth
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.